AbbVie Inc. income statement & cash flow
In the fiscal year ended Dec 31, 2025, AbbVie Inc. reported net income of $4.23B on revenue of $61.16B. Operating cash flow was $19.03B and capital expenditures were $1.21B, leaving $17.82B of free cash flow (operating cash flow minus capital expenditures).
Income statement and cash flow summary
| Fiscal year ended | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $25.64B | $28.22B | $32.75B | $33.27B | $45.80B | $56.20B | $58.05B | $54.32B | $56.33B | $61.16B |
| Operating income | $9.34B | $9.54B | $6.38B | $12.98B | $11.36B | $17.92B | $18.12B | $12.76B | $9.14B | $15.07B |
| Net income | $5.95B | $5.31B | $5.69B | $7.88B | $4.62B | $11.54B | $11.84B | $4.86B | $4.28B | $4.23B |
| Diluted EPS | $3.63 | $3.30 | $3.66 | $5.28 | $2.72 | $6.45 | $6.63 | $2.72 | $2.39 | $2.36 |
| Operating cash flow | $7.04B | $9.96B | $13.43B | $13.32B | $17.59B | $22.78B | $24.94B | $22.84B | $18.81B | $19.03B |
| Capital expenditures | $479.00M | $529.00M | $638.00M | $552.00M | $798.00M | $787.00M | $695.00M | $777.00M | $974.00M | $1.21B |
| Reported in | 10-K 2019 | 10-K 2020 | 10-K 2021 | 10-K 2022 | 10-K 2023 | 10-K 2024 | 10-K 2025 | 10-K 2026 | 10-K 2026 | 10-K 2026 |
Margins
Each figure divided by revenue for the same fiscal year.
| Fiscal year ended | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| Dec 2025 | — | 24.6% | 6.9% |
| Dec 2024 | — | 16.2% | 7.6% |
| Dec 2023 | — | 23.5% | 9.0% |
| Dec 2022 | — | 31.2% | 20.4% |
| Dec 2021 | — | 31.9% | 20.5% |
Source: SEC EDGAR XBRL company facts for CIK 1551152 (raw data). Most recent filing in this dataset: 10-Q filed Nov 3, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.